Aurobindo Pharma

Aurobindo Pharma Overview

Company Headquarters: Hyderabad, Andhra Pradesh

Founded: 1986

Workforce: 5,001-10,000

Company Working: Aurobindo Pharma is a vertically integrated pharmaceutical company that delivers innovative solutions. The company manufactures and sells over 300 products in over 150 countries across the globe through six major therapeutic segments such as antibiotics, anti-retroviral, CVS, CNS, gastroenterological, and anti-allergic. Through cost-effective manufacturing capabilities and a few loyal customers, the company has entered into the high margin specialty generic formulations segment. Aurobindo Pharma has evolved into a knowledge-driven company manufacturing active pharmaceutical ingredients and formulation products. It is R&D focused and has a multi-product portfolio with manufacturing facilities in several countries.

Strategy

Aurobindo Pharma invests a large amount of money and human on research and development activities and is involved in mergers and acquisitions for geographical expansions. The company also believes in generating maximum revenue from established markets and new product launches to achieve organic growth.

Company Snapshot

$2,081.25M

Revenue

10,000

Employees

1986

Founded

Hyderabad, Andhra Pradesh

Headquarters

SWOT Analysis

Strengths

The company focuses on achieving organic growth
Strong position in the generics market
Strong focus on research and innovation to develop pharmaceutical products
Strong product pipeline

Weaknesses

Maximum revenue generation from the generics segment
Limited presence in Europe
Product recalls

Opportunities

Collaborations may enhance the company’s innovative drug pipeline Mergers and acquisitions New product launches
Mergers and acquisitions
New product launches
Collaborations may enhance the company’s innovative drug pipeline

Threats

Healthcare cost restraints, efforts, and pricing pressures may affect the company's future revenues

Key Developments

Date	Approach	Development
September 2018	Acquisition	Aurobindo Pharma acquired three commercial operations and manufacturing units from Sandoz and Novartis. This acquisition would help the company to expand its geographical boundaries.
September 2018	Acquisition	Aurobindo Pharma acquired the dermatology and oral solids business from Sandoz, Inc., US. With this, the company has become the second largest generic player in the US by a number of prescriptions.
July 2018	Acquisition	Aurobindo signed a definitive agreement to acquire Apotex’s businesses in five European countries, namely, Czech Republic, Poland, the Netherlands, Spain, and Belgium.
January 2017	Acquisition	Aurobindo acquired Generis Farmaceutica S.A. With this, the company has got access to the manufacturing and sale of pharmaceutical products in Portugal.

Product Offering

Aurobindo Pharma
- Prils
- Cardiovascular

Financial Performance

What our clients say

Trusted by forward-thinking businesses
for data-driven intelligence

Noah Malgeri

Co-Founder, Mojave Rail Fabrication Limited

This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.

Michael Robert

Manager, JavolVision

Thanks, I am so happy that we worked together. Maybe we still can work together in the future.

Joseph Aguayo

Sales Operations & Pricing Manager, Intel

Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.

Bong Lau

Sales Leader, Bamberg

We bought your "2025 report" in 2020. Everything is fine and very good.

Peter Groot Koerkamp

Account and Business Manager, EFS-Holland BV

Thanks for sending the report it gives us a good global view of the Betaïne market.

Younghwan Choi

Senior Retail Manager, LG Chem

We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.

Mark Irwin

Management Consultant, Level 21

I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.

Rob Kooiker

Group Product Manager HVAC & Fire Protection GMA, Rockwool

I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!

Jason Lee

R&D Director, Seojin

Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.

Akif Moroglu

Strategy & Business Development Director, Dogan Holding

We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.